Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX)

Historical Holders from Q2 2018 to Q3 2025

Symbol
AMRX on Nasdaq
Type / Class
Equity / Class A Common Stock, par value $0.01
Shares outstanding
316M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
150M
Holdings value
$1.5B
% of all portfolios
0.003%
Grand Portfolio weight change
+0%
Number of holders
243
Number of buys
131
Number of sells
-103
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Patel Tushar Bhikhubhai 15.7% $363M 48.6M Patel Tushar Bhikhubhai 14 Mar 2025
Patel Chintu 8.2% $259M 25.9M Patel Chintu 03 Oct 2025
Patel Dipan 7.6% -1.25% $239M 23.8M 0% Patel Dipan 03 Oct 2025
Patel Chirag K. 7.1% $179M 22.2M Patel Chirag K. 06 Aug 2025
Mahesh Akram 6.56% $154M 20.6M Akram Mahesh 31 Mar 2025
VANGUARD GROUP INC 5.02% $118M 15.8M The Vanguard Group 31 Mar 2025

Institutional Holders of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 150M $1.5B +$81M $10.01 243
2025 Q2 142M $1.15B +$54.5M $8.09 237
2025 Q1 135M $1.13B +$84.5M $8.38 232
2024 Q4 126M $997M -$136M $7.92 194
2024 Q3 143M $1.19B +$32.3M $8.32 180
2024 Q2 139M $880M +$192M $6.35 179
2024 Q1 108M $655M -$6.55M $6.06 173
2023 Q4 109M $663M +$52.7M $6.07 151
2023 Q3 102M $430M +$19.7M $4.22 141
2023 Q2 97.4M $302M +$4.22M $3.10 122
2023 Q1 96.9M $135M -$8.21M $1.39 142
2022 Q4 102M $203M +$4.46M $1.99 155
2022 Q3 99.5M $201M -$1.68M $2.02 144
2022 Q2 99.4M $316M -$2.1M $3.18 140
2022 Q1 100M $417M -$2.78M $4.17 154
2021 Q4 101M $481M -$751K $4.79 148
2021 Q3 100M $535M +$2.52M $5.34 150
2021 Q2 99.9M $512M -$13.1M $5.12 153
2021 Q1 102M $684M +$24.8M $6.73 155
2020 Q4 99.5M $455M -$9.01M $4.57 128
2020 Q3 101M $394M -$1.37M $3.88 133
2020 Q2 102M $484M +$16.6M $4.76 131
2020 Q1 98.3M $342M -$17.3M $3.48 117
2019 Q4 101M $488M -$9.61M $4.82 116
2019 Q3 108M $314M -$46M $2.90 111
2019 Q2 105M $756M -$88.1M $7.17 116
2019 Q1 109M $1.54B -$98M $14.17 150
2018 Q4 116M $1.57B +$89.7M $13.53 157
2018 Q3 108M $2.41B +$283M $22.19 162
2018 Q2 97.5M $1.6B +$1.6B $16.41 163